1 / 3

High Throughput Screening Market worth $29.29 Billion by 2027

The report "High Throughput Screening Market by Technology (Cell-Based Assays, Lab on a Chip, Bioinformatics), Application (Target Identification, Primary Screening, Toxicology), Product (Reagent, Instruments, Software, Service), End User - Global Forecast to 2027".

Télécharger la présentation

High Throughput Screening Market worth $29.29 Billion by 2027

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript


  1. High Throughput Screening Market worth $29.29 Billion by 2027 The report "High Throughput Screening Market by Technology (Cell-Based Assays, Lab on a Chip, Bioinformatics), Application (Target Identification, Primary Screening, Toxicology), Product (Reagent, Instruments, Software, Service), End User - Global Forecast to 2027", is expected to reach USD 29.29 billion by 2027 from an estimated USD 14.95 billion in 2019, at a CAGR of 7.8%. The major factors driving the growth of the HTS market include initiatives undertaken by pharmaceutical and biotechnology companies, increasing R&D spending, technological advancements in HTS, and the availability of government funding and venture capital investments. View detailed Table of Content here - https://www.marketsandmarkets.com/Market- Reports/high-throughput-screening-market-134981950.html By product and service, the reagents & assay kits segment accounted for the largest share of the HTS market in 2018 On the basis of product and service, the reagents & assay kits segment accounted for the largest share of the global HTS market. The large share of this segment can be attributed to factors such as the large numbers of reagents and assay kits used in HTS techniques, rising prevalence of a number of diseases, increasing pharmaceutical R&D, and increased government funding for life science research. Download PDF Brochure: - https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=134981950 By technology, the cell-based assays segment held the largest share in 2018 Based on technology, the HTS market is segmented into cell-based assays, lab-on-a-chip (LOC), ultra-high-throughput screening (uHTS), label-free technology, and bioinformatics. In 2018, the cell-based assays segment accounted for the largest share of the HTS market. The large share of this segment can be attributed to its increased use in cell culture techniques, especially 2D cell culture. By end user, the pharmaceutical and biotechnology companies segment held the largest share of the HTS market in 2018 Based on end user, the pharmaceutical and biotechnology companies segment accounted for the largest share of the HTS market. Factors such as the increasing use of HTS techniques by

  2. pharmaceutical and biotechnology companies for drug discovery applications along with the increasing pharmaceutical R&D expenditure are driving the growth of this segment. North America dominated the market in 2018 North America accounted for the largest share of the HTS market in 2018, followed by Europe and Asia Pacific. The large spending on pharmaceutical R&D, growing adoption of HTS, availability of government funding, and the presence of major key players in the region are the major factors responsible for the large share of the North American HTS market. Read more: - https://www.marketsandmarkets.com/PressReleases/high-throughput- screening.asp The prominent players in the global HTS market are Agilent (US), Danaher (US), Thermo Fisher Scientific (US), PerkinElmer (US), Tecan (Switzerland), Axxam (Italy), Merck Group (Germany), Bio-Rad (US), Hamilton (US), Corning (US), BioTek (US), and Aurora Biomed (Canada). About MarketsandMarkets™ MarketsandMarkets™ provides quantified B2B research on 30,000 high growth niche opportunities/threats which will impact 70% to 80% of worldwide companies’ revenues. Currently servicing 7500 customers worldwide including 80% of global Fortune 1000 companies as clients. Almost 75,000 top officers across eight industries worldwide approach MarketsandMarkets™ for their painpoints around revenues decisions. Our 850 fulltime analyst and SMEs at MarketsandMarkets™ are tracking global high growth markets following the "Growth Engagement Model – GEM". The GEM aims at proactive collaboration with the clients to identify new opportunities, identify most important customers, write "Attack, avoid and defend" strategies, identify sources of incremental revenues for both the company and its competitors. MarketsandMarkets™ now coming up with 1,500 MicroQuadrants (Positioning top players across leaders, emerging companies, innovators, strategic players) annually in high growth emerging segments. MarketsandMarkets™ is determined to benefit more than 10,000 companies this year for their revenue planning and help them take their innovations/disruptions early to the market by providing them research ahead of the curve. MarketsandMarkets’s flagship competitive intelligence and market research platform, "Knowledgestore" connects over 200,000 markets and entire value chains for deeper understanding of the unmet insights along with market sizing and forecasts of niche markets. Contact: Mr. Shelly Singh MarketsandMarkets™ INC. 630 Dundee Road Suite 430 Northbrook, IL 60062

  3. USA : 1-888-600-6441 sales@marketsandmarkets.com

More Related